Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial.

Ariotti, Sara; van Leeuwen, Maarten; Brugaletta, Salvatore; Leonardi, Sergio; Akkerhuis, Kristiaan Martijn; Rexhaj, Emrush; Janssens, Gladys; Ortega-Paz, Luis; Rizzotti, Diego; van den Berge, Jan C; Heg, Dierik Hans; Francolini, Gloria; Windecker, Stephan; Valgimigli, Marco (2017). Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. American Heart Journal, 189, pp. 128-136. Elsevier 10.1016/j.ahj.2017.03.017

[img] Text
1-s2.0-S0002870317301102-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (879kB) | Request a copy

BACKGROUND Among the 3 approved oral P2Y12 inhibitors for the treatment for patients with acute coronary syndrome (ACS), ticagrelor, but not prasugrel or clopidogrel, has been associated with off-target properties, such as improved endothelial-dependent vasomotion and increased adenosine plasma levels. METHODS The HI-TECH study (NCT02587260) is a multinational, randomized, open-label, crossover study with a Latin squares design, conducted at 5 European sites, in which patients free from recurrent ischemic or bleeding events ≥30 days after a qualifying ACS were allocated to sequentially receive a 30 ± 5-day treatment with prasugrel, clopidogrel, and ticagrelor in random order. The primary objective was to evaluate whether ticagrelor, at treatment steady state (ie, after 30 ± 5 days of drug administration), as compared with both clopidogrel and prasugrel, is associated with an improved endothelial function, assessed with peripheral arterial tonometry. Thirty-six patients undergoing evaluable endothelial function assessment for each of the assigned P2Y12 inhibitor were needed to provide 90% power to detect a 10% relative change of the reactive hyperemia index in the ticagrelor group. CONCLUSION The HI-TECH study is the first randomized, crossover study aiming to ascertain whether ticagrelor, when administered at approved regimen in post-ACS patients, improves endothelial function as compared with both clopidogrel and prasugrel.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Ariotti, Sara; Rexhaj, Emrush; Heg, Dierik Hans; Windecker, Stephan and Valgimigli, Marco

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0002-8703

Publisher:

Elsevier

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

12 Feb 2018 12:19

Last Modified:

12 Feb 2018 12:19

Publisher DOI:

10.1016/j.ahj.2017.03.017

PubMed ID:

28625369

BORIS DOI:

10.7892/boris.111089

URI:

https://boris.unibe.ch/id/eprint/111089

Actions (login required)

Edit item Edit item
Provide Feedback